These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25216971)

  • 1. Imported fire ant rush desensitization using omalizumab and a premedication regimen.
    Tille KS; Parker AL
    Ann Allergy Asthma Immunol; 2014 Nov; 113(5):574-6. PubMed ID: 25216971
    [No Abstract]   [Full Text] [Related]  

  • 2. Imported fire ant hypersensitivity: a 1-day rush immunotherapy schedule without premedication.
    Dietrich JJ; Moore LM; Nguyen S; Hagan LL; Tankersley MS
    Ann Allergy Asthma Immunol; 2009 Dec; 103(6):535-6. PubMed ID: 20084848
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy.
    Nadeau KC; Schneider LC; Hoyte L; Borras I; Umetsu DT
    J Allergy Clin Immunol; 2011 Jun; 127(6):1622-4. PubMed ID: 21546071
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg.
    Lafuente I; Mazon A; Nieto M; Uixera S; Pina R; Nieto A
    Pediatr Allergy Immunol; 2014 Nov; 25(7):717-9. PubMed ID: 24902874
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful use of omalizumab for prevention of fire ant anaphylaxis.
    Tartibi HM; Majmundar AR; Khan DA
    J Allergy Clin Immunol; 2010 Sep; 126(3):664-5. PubMed ID: 20673977
    [No Abstract]   [Full Text] [Related]  

  • 6. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
    Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
    J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful administration of a 1-day imported fire ant rush immunotherapy protocol.
    Judd CA; Parker AL; Meier EA; Tankersley MS
    Ann Allergy Asthma Immunol; 2008 Sep; 101(3):311-5. PubMed ID: 18814455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.
    Soriano Gomis V; Gonzalez Delgado P; Niveiro Hernandez E
    J Investig Allergol Clin Immunol; 2008; 18(3):225-6. PubMed ID: 18564638
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab. An option in vernal keratoconjunctivitis?
    Sánchez J; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):319-20. PubMed ID: 21975146
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab.
    von Websky A; Reich K; Steinkraus V; Breuer K
    J Dtsch Dermatol Ges; 2013 Jul; 11(7):677-8. PubMed ID: 23575040
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of a bullous urticaria with omalizumab.
    Ozturk AB; Kocaturk E; Ozturk E
    Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of immunmodulators in allergen-specific immunotherapy.
    Kopp MV
    Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
    Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
    Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 15. The stinging impact of the imported fire ant.
    Tankersley MS
    Curr Opin Allergy Clin Immunol; 2008 Aug; 8(4):354-9. PubMed ID: 18596594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
    Wu KCP; Jabbar-Lopez ZK
    J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.
    Ojaimi S; Harnett PR; Fulcher DA
    J Allergy Clin Immunol Pract; 2014; 2(1):105-6. PubMed ID: 24565780
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.
    Cavelti-Weder C; Muggli B; Keller C; Babians-Brunner A; Biason-Lauber A; Donath MY; Schmid-Grendelmeier P
    Diabetes Care; 2012 Jun; 35(6):e41. PubMed ID: 22619293
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of in vivo and in vitro tests in the diagnosis of imported fire ant sting allergy.
    Stafford CT; Moffitt JE; Bunker-Soler A; Hoffman DR; Thompson WO
    Ann Allergy; 1990 Apr; 64(4):368-72. PubMed ID: 2321813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.